Vaxart Stockholders Reject Reverse Stock Split Proposal

Vaxart ( (VXRT) ) has issued an announcement.

On June 13, 2025, Vaxart held its reconvened 2025 annual meeting of stockholders, where two proposals were approved and two were rejected. Stockholders elected six directors and ratified the selection of WithumSmith+Brown, PC as the company’s independent accounting firm. However, they did not approve an amendment for a reverse stock split or the 2024 executive compensation plan. The company is evaluating its options following the rejection of the reverse stock split proposal and has canceled a special meeting previously scheduled for June 30, 2025.

The most recent analyst rating on (VXRT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.

Spark’s Take on VXRT Stock

According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.

Vaxart’s stock score is driven by significant clinical trial progress and strong technical indicators, tempered by financial performance challenges, valuation issues, and strategic uncertainties. While corporate events offer growth potential, ongoing operational and financial hurdles cannot be overlooked.

To see Spark’s full report on VXRT stock, click here.

More about Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered as pills, which can be stored and shipped without refrigeration, eliminating the risk of needle-stick injury. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).

Average Trading Volume: 4,191,655

Technical Sentiment Signal: Sell

Current Market Cap: $150.7M

For a thorough assessment of VXRT stock, go to TipRanks’ Stock Analysis page.